Anti-TNFR2 monoclonal antibody LBL-019 in patients with advanced malignant tumors: A phase I, first-in-human, open-label, multicenter, dose escalation Study.

被引：0
|
作者：
Zhou, Fei
Li, Wei
Chen, Yu
Lin, Jing
Chen, Ling
Zhang, Huishan
Dong, Xiaorong
Tong, Fan
Zhang, Ruiguang
Yin, Yongmei
Liang, Yan
Yang, Nong
Hu, Sheng
Zhuang, Wei
Li, Tao
Cai, Shengli
Zhou, Caicun
机构：
[1] Tongji Univ, Shanghai Pulm Hosp, Dept Med Oncol, Sch Med, Shanghai, Peoples R China
[2] Tongji Univ, Thorac Canc Inst, Sch Med, Shanghai, Peoples R China
[3] Fujian Canc Hosp, Dept Oncol, Fuzhou, Peoples R China
[4] Fujian Canc Hosp, Fuzhou, Peoples R China
[5] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China
[6] Nanjing Med Univ, Dept Oncol, Affiliated Hosp 1, Nanjing, Peoples R China
[7] Hunan Canc Hosp, Lung Gastrointestinal & Oncol Dept, Changsha, Peoples R China
[8] Hubei Canc Hosp, Dept Internal Med Oncol, Wuhan, Peoples R China
[9] Nanjing Leads Biolabs Co Ltd, Nanjing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14580
引用
收藏
页数：1
相关论文
共 50 条
  • [41] First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas
    Piha-Paul, Sarina A.
    Geva, Ravit
    Tan, Tira J.
    Lim, Darren Wt
    Hierro, Cinta
    Doi, Toshikiko
    Rahma, Osama
    Lesokhin, Alexander
    Luke, Jason John
    Otero, Javier
    Nardi, Lisa
    Singh, Angad
    Xyrafas, Alexandros
    Chen, Xinhui
    Mataraza, Jennifer
    Bedard, Philippe L.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (08)
  • [42] A First-in-Human Phase I Study of CTX-712 in Patients with Advanced, Relapsed or Refractory Malignant Tumors Hematologic Malignancies Dose Escalation Cohort
    Yokoyama, Hisayuki
    Ando, Koji
    Fukuhara, Noriko
    Iida, Hiroatsu
    Fukuhara, Suguru
    Miyake, Hiroshi
    Tanoue, Yasushi
    Yamamoto, Maki
    Tozaki, Hirokazu
    Mizutani, Akio
    Morishita, Daisuke
    Takeyama, Kunihiko
    Shimizu, Toshio
    Yamamoto, Noboru
    BLOOD, 2022, 140 : 6211 - 6212
  • [43] A phase I, open label, multicenter dose escalation study of AZD2811 nanoparticle in patients with advanced solid tumors.
    Johnson, Melissa Lynne
    Cosaert, Jan G. C. E.
    Falchook, Gerald Steven
    Jones, Suzanne Fields
    Strickland, Donald
    Greenlees, Carol
    Charlton, Julie
    MacDonald, Alexander
    Overend, Philip
    Adelman, Carrie
    Burris, Howard A.
    Pease, Elizabeth J.
    Patel, Gargi Surendra
    Wang, Judy Sing-Zan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [44] A First-in-Human Phase I Study of MORAb-004, a Monoclonal Antibody to Endosialin in Patients with Advanced Solid Tumors
    Diaz, Luis A., Jr.
    Coughlin, Christina M.
    Weil, Susan C.
    Fishel, Jean
    Gounder, Mrinal M.
    Lawrence, Susan
    Azad, Nilofer
    O'Shannessy, Daniel J.
    Grasso, Luigi
    Wustner, Jason
    Ebel, Wolfgang
    Carvajal, Richard D.
    CLINICAL CANCER RESEARCH, 2015, 21 (06) : 1281 - 1288
  • [45] A First-in-Human, Open-Label, Phase I Dose Escalation Trial of Daily Oral Nmt Inhibitor Zelenirstat in Patients with Relapsed/Refractory B-Cell Lymphomas and Advanced Solid Tumors
    Sangha, Randeep
    Jamal, Rahima
    Spratlin, Jennifer
    Kuruvilla, John
    Sehn, Laurie H.
    Weickert, Michael
    Berthiaume, Luc
    Mackey, John Robert
    BLOOD, 2023, 142
  • [46] A first-in-human phase Ia open-label dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) administered intravenously in patients with advanced solid tumors.
    Rosen, L. S.
    Gordon, M. S.
    Bai, S.
    Hegde, P.
    Fredrickson, J.
    Chen, D. S.
    Chang, I.
    Funke, R. P.
    Chandler, G. S.
    Naumovski, L.
    Munster, P. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [47] A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma
    Sia, Hanlon
    Tan, Peter T.
    Richter, Joshua
    Ho, Phoebe Joy
    Cochrane, Tara
    Quach, Hang
    Dhakal, Binod
    Proscurshim, Igor
    Jiang, Tony
    Mancino, Emaryn
    Salhi, Yacine
    Stefano, Sammicheli
    Gudi, Girish
    Garton, Andrew
    Feldman, Eric J.
    Spencer, Andrew
    BLOOD, 2022, 140 : 10182 - 10184
  • [48] A phase I, first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-3654 administered daily for 28 days to patients with advanced solid tumors.
    Garrido-Laguna, Ignacio
    Dillon, Patrick Michael
    Anthony, Stephen Patrick
    Janat-Amsbury, Margit
    Ashenbramer, Nissa
    Warner, Steven L.
    Mouritsen, Lars
    Wade, Mark L.
    Whatcott, Clifford
    Bearss, David
    Fu, Siqing
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [49] Subcutaneous delivery of amivantamab in patients with advanced solid malignancies: PALOMA, an open-label, multicenter, dose escalation phase 1b study.
    Krebs, Matthew
    Johnson, Melissa Lynne
    Cho, Byoung Chul
    Park, Keunchil
    Haddish-Berhane, Nahor
    Zemlickis, Donna
    Mitselos, Anna
    Meacle, Francis
    Knoblauch, Roland Elmar
    Hellemans, Peter
    Minchom, Anna Rachel
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [50] Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A
    Taylor, Claribel P.
    Tummala, Sanjeev
    Molrine, Deborah
    Davidson, Lisa
    Farrell, Richard J.
    Lembo, Anthony
    Hibberd, Patricia L.
    Lowy, Israel
    Kelly, Ciaran P.
    VACCINE, 2008, 26 (27-28) : 3404 - 3409
12345